PARP1 and neoplasm: In addition, the two PARP inhibitors possess distinct biophysical characteristics (18), which provides an explanation that, as PARP inhibitors in targeting DNA damage/repair deficiency, Niraparib is more potent in killing tumor cells than Olaparib.